You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 7,410,945

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,410,945

Title:	Treatment of inflammatory bowel disease
Abstract:	This invention relates to methods of treatment of inflammatory bowel disease, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the methods of the invention are disclosed.
Inventor(s):	Woodruff; Trent Martin (Brisbane, AU), Taylor; Stephen Maxwell (Bellbird Park, AU), Fairlie; David (Springwood, AU)
Assignee:	The University of Queensland (Brisbane, AU)
Application Number:	10/531,564
Patent Claims:	1. A method of treating ulcerative colitis, comprising administering an effective amount of the compound AcPhe[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] to a subject in need thereof. 2. A method of relieving or ameliorating the effects of ulcerative colitis, comprising administering an effective amount of the compound AcPhe[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] to a subject in need thereof. 3. The method of claim 1 or claim 2, wherein said compound has potent antagonist activity at sub-micromolar concentrations. 4. The method of claim 1 or claim 2, wherein said compound has a receptor affinity IC.sub.50 <25 .mu.M, and an antagonist potency IC.sub.50 <1 .mu.M. 5. The method of claim 1 or claim 2, wherein said subject is human. 6. The method of claim 1 or claim 2, wherein said compound is administered to said subject in conjunction with one or more other agents for the treatment of ulcerative colitis. 7. The method of claim 6, wherein said one or more other agents comprise an inhibitor of TNF-.alpha. or C3a. 8. The method of claim 7, wherein said inhibitor of TNF-.alpha. is infliximab. 9. The method of claim 7, wherein said inhibitor of C3a is compound SB 290157, which has the formula (Ph.sub.2CHCH.sub.2OCH.sub.2CO-Arg-OH).

Details for Patent 7,410,945

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2022-10-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.